| Title: | Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells |
| Other Titles: | An importance of IL-34 in cancer chemoresistance |
| Authors: | Baghdadi, Muhammad Browse this author |
| Wada, Haruka Browse this author →KAKEN DB |
| Nakanishi, Sayaka Browse this author |
| Abe, Hirotake Browse this author |
| Han, Nanumi Browse this author |
| Putra, Wira Eka Browse this author |
| Endo, Daisuke Browse this author |
| Watari, Hidemichi Browse this author →KAKEN DB |
| Sakuragi, Noriaki Browse this author →KAKEN DB |
| Hida, Yasuhiro Browse this author →KAKEN DB |
| Kaga, Kichizo Browse this author →KAKEN DB |
| Miyagi, Yohei Browse this author →KAKEN DB |
| Yokose, Tomoyuki Browse this author |
| Takano, Atsushi Browse this author →KAKEN DB |
| Daigo, Yataro Browse this author →KAKEN DB |
| Seino, Ken-ichiro Browse this author →KAKEN DB |
| Issue Date: | Oct-2016 |
| Publisher: | American Association for Cancer Research |
| Journal Title: | Cancer research |
| Volume: | 76 |
| Issue: | 20 |
| Start Page: | 6030 |
| End Page: | 6042 |
| Publisher DOI: | 10.1158/0008-5472.CAN-16-1170 |
| PMID: | 27550451 |
| Abstract: | The ability of tumor cells to escape immune destruction and their acquired resistance to chemotherapy are major obstacles to effective cancer therapy. Although immune checkpoint therapies such as anti-PD-1 address these issues in part, clinical responses remain limited to a subpopulation of patients. In this report, we identified IL34 produced by cancer cells as a driver of chemoresistance. In particular, we found that IL34 modulated the functions of tumor-associated macrophages to enhance local immunosuppression and to promote the survival of chemoresistant cancer cells by activating AKT signaling. Targeting IL34 in chemoresistant tumors resulted in a remarkable inhibition of tumor growth when accompanied with chemotherapy. Our results define a pathogenic role for IL34 in mediating immunosuppression and chemoresistance and identify it as a tractable target for anticancer therapy. |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/67225 |
| Appears in Collections: | 遺伝子病制御研究所 (Institute for Genetic Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
